Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment. (Optimise)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00681850
First received: May 19, 2008
Last updated: June 1, 2010
Last verified: June 2010

May 19, 2008
June 1, 2010
March 2008
January 2010   (final data collection date for primary outcome measure)
HbA1c, LDL-cholesterol, Systolic Blood Pressure [ Time Frame: Visit 1; Visit 2 (after approximately 4 months after visit 1); Visit 3 (after approximately 8 months after visit 1); Visit 4 (after approximately 12 months after visit 1) ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00681850 on ClinicalTrials.gov Archive Site
Glycaemia, Triglycerides, Total and HDL-Cholesterol, Diastolic Blood Pressure, Waist circumference, Smoking habits, Microalbuminuria, Body Mass Index, Physical activity (Rating scale and step counter), Degree of ophthalmic control and dietary advice [ Time Frame: Visit 1Visit 2 (after approximately 4 months after visit 1)Visit 3 (after approximately 8 months after visit 1)Visit 4 (after approximately 12 months after visit 1) ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.
OPtimal Type 2 dIabetes Management Including Benchmarking and Standard trEatment.

Demonstrate that the use of benchmarking improves quality of patient care, in particular the control of diabetes, lipids and blood pressure, by determining the percentage of patients in the benchmarking group achieving pre-set targets for HbA1c 14,18, LDL-cholesterol16,18 and Systolic Blood Pressure17,18 versus control group (non-benchmarking group) after 12 months of follow-up.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample

General Practioners

Diabetes
Not Provided
  • 1
    Control group
  • 2
    Benchmarking group

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4027
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Provision of informed Consent
  • Patients suffering from diabetes type II, insulin dependent or not insulin dependent.

Exclusion Criteria:

  • Type I diabetes
  • Pregnancy diabetes
  • Hospitalisation, as this is a primary care study
  • Patients who are member of the Belgian Diabetes Convention
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   Greece,   Luxembourg,   Portugal,   Spain,   United Kingdom
 
NCT00681850
D3560L00071
No
Eugène Vissers, MD, Therapeutic Area Leader Cardivascular and Diabetes., AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Principal Investigator: Hermans, M. Prof. UCL
AstraZeneca
June 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP